论文部分内容阅读
目的探讨低剂量干扰素联合利巴韦林治疗丙肝(丙型肝炎)代偿期肝硬化的临床价值。方法 36例丙肝代偿期肝硬化患者作为研究对象,随机分为对照组和观察组,各18例。对照组单纯给予利巴韦林治疗,观察组给予低剂量干扰素联合利巴韦林治疗,比较两组患者的临床效果。结果观察组的丙型肝炎病毒核糖核苷酸(HCV-RNA)阴转率、持续病毒学应答率及谷丙转氨酶(ALT)复常率分别为77.78%、83.33%、83.33%,均高于对照组的50.00%、55.56%、55.56%,差异均有统计学意义(P<0.05);观察组不良反应发生率为33.33%,高于对照组的11.11%,差异有统计学意义(P<0.05);观察组死亡率低于对照组,差异有统计学意义(P<0.05)。结论丙肝代偿期肝硬化患者采用低剂量干扰素联合利巴韦林治疗安全且疗效显著,可降低死亡率。
Objective To investigate the clinical value of low-dose interferon combined with ribavirin in the treatment of decompensated cirrhosis of hepatitis C (hepatitis C). Methods Thirty-six patients with decompensated cirrhosis of hepatitis C were randomly divided into control group and observation group, with 18 cases in each. The control group was treated with ribavirin alone. The observation group was treated with low-dose interferon plus ribavirin. The clinical effects of the two groups were compared. Results The HCV-RNA negative rate, continuous virological response rate and ALT normal rate in the observation group were 77.78%, 83.33% and 83.33% respectively, both higher than The difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 33.33%, which was higher than that in the control group (11.11%), the difference was statistically significant (P < 0.05). The death rate in the observation group was lower than that in the control group, with significant difference (P <0.05). Conclusion Hepatitis C patients with decompensated cirrhosis using low-dose interferon combined with ribavirin treatment of safety and efficacy, reduce mortality.